Detalhe da pesquisa
1.
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Curr Opin Oncol
; 35(4): 288-291, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222199
2.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
3.
Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features.
Int J Gynecol Cancer
; 2023 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38054268
4.
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8302-8314, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976464
5.
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Int J Mol Sci
; 23(7)2022 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35408919
6.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Int J Mol Sci
; 21(12)2020 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575899
7.
Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8319, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36131118
8.
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8317-8318, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36109407
9.
BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.
Front Oncol
; 14: 1354427, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38544832
10.
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Tumori
; 109(5): 490-495, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609207
11.
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1247291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37781174
12.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1357793, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318323
13.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Cancers (Basel)
; 16(1)2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201470
14.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Cancers (Basel)
; 15(4)2023 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831376
15.
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Cancers (Basel)
; 15(14)2023 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509300
16.
Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma.
Expert Rev Anticancer Ther
; 22(10): 1039-1047, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111897
17.
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.
Front Oncol
; 12: 880008, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35692798
18.
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
Front Oncol
; 11: 689829, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195090
19.
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
Cells
; 10(12)2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34943916
20.
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience.
Cancers (Basel)
; 12(8)2020 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785193